SCHEMBL27623966

SCHEMBL27623966

O=C(c1ccc(-c2ccsc2)cc1)c1ccc(-c2ccsc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 4/20 0.56
CYP2A6 P11509 2/20 0.52
CYP2E1 P05181 1/20 0.52
CYP2B6 P20813 1/20 0.52
LTA4H P09960 1/20 0.51
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
ACMSD Q8TDX5 1/20 0.49
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
CHEK1 O14757 1/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
LCK P06239 1/20 0.45
FYN P06241 1/20 0.45
DAO P14920 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203627 0.85 LCK (0.59) CHEK2CYP2A6CYP2E1CYP2B6MMP2
SCHEMBL6516791 0.83 HSD17B1 (0.55) CHEK2CYP2A6CYP2E1CYP2B6MMP2
SCHEMBL7334475 0.83 CHEK2 (0.53) CHEK2CYP2A6CYP2E1CYP2B6LTA4H
SCHEMBL7639339 0.83 CHEK2 (0.57) CHEK2CYP2A6CYP2E1CYP2B6LTA4H
SCHEMBL30898463 0.83 CHEK2 (0.76) CHEK2CYP2A6CYP2E1CYP2B6MMP2
SCHEMBL27989815 0.81 CYP2A6 (0.74) CHEK2CYP2A6CYP2E1CYP2B6ACMSD
SCHEMBL5944164 0.80 HDAC1 (0.63) CHEK2MMP2MMP9MMP8
SCHEMBL12670300 0.79 SMN1; SMN2 (0.59) CHEK2CYP2A6CYP2E1CYP2B6LTA4H
SCHEMBL12632181 0.79 CHEK2 (0.53) CHEK2CYP2A6CYP2E1CYP2B6MMP2
SCHEMBL12582092 0.79 CHEK2 (0.49) CHEK2CYP2A6CYP2E1CYP2B6MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102906093-B NK-3 receptor selective antagonists compound, pharmaceutical composition and the using method in the receptor-mediated disease of NK-3 EUROSCREEN S.A. (BE) 2016-01-13 CN claimed
CN-102906093-A Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders EUROSCREEN SA 2013-01-30 CN claimed
CN-100343256-C Biaryl substituted diazabicycloalkane amides as nicotinic acetylcholine agonists ASTRAZENECA AB (SE) 2007-10-17 CN claimed
CN-1678615-A Biaryl substituted diazabicycloalkanes as nicotinic acetylcholine antagonists ASTRAZENECA AB (SE) 2005-10-05 CN claimed
CN-100343256-C Biaryl substituted diazabicycloalkane amides as nicotinic acetylcholine agonists ASTRAZENECA AB (SE) 2007-10-17 CN disclosed
CN-1678615-A Biaryl substituted diazabicycloalkanes as nicotinic acetylcholine antagonists ASTRAZENECA AB (SE) 2005-10-05 CN disclosed